New Drug Offers Greater Hope for Some Patients with Lung Cancer | UCLA Vital Signs

For the vast majority of patients with lung cancer, advances in treatment have been minimal. Chemotherapy remains the standard of care, and for those whose cancer worsens during or after initial treatment, the outcome of so-called second-line therapy has been poor: Only about 10 percent of patients show any improvement, and the average length of survival is several months.